Se-Hoon Lee, MD, an oncologist at the Samsung Medical Center in Seoul, Korea, discusses his focus of research in the lung cancer space, including the phase 1 CHRYSALIS study of amivantamab and lazertinib in patients with EGFR-mutated non–small cell lung cancer.
